These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. To study the usefulness and comparison of myocardial strain imaging by 2D and 3D echocardiography for early detection of cardiotoxicity in patients undergoing cardiotoxic chemotherapy. Alam S; Chandra S; Saran M; Chaudhary G; Sharma A; Bhandhari M; Vishwakarma P; Pradhan A; Sethi R; Dwivedi SK; Narain VS Indian Heart J; 2019; 71(6):468-475. PubMed ID: 32248920 [TBL] [Abstract][Full Text] [Related]
5. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography. Villani F; Meazza R; Materazzo C Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568 [TBL] [Abstract][Full Text] [Related]
7. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961 [TBL] [Abstract][Full Text] [Related]
8. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. Nousiainen T; Vanninen E; Rantala A; Jantunen E; Hartikainen J J Intern Med; 1999 Apr; 245(4):359-64. PubMed ID: 10356598 [TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin. Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095 [TBL] [Abstract][Full Text] [Related]
10. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Skubitz KM; Blaes AH; Konety SH; Francis GS Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562 [TBL] [Abstract][Full Text] [Related]
11. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Nousiainen T; Jantunen E; Vanninen E; Hartikainen J Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452 [TBL] [Abstract][Full Text] [Related]
12. Ultrasonic analysis of anthracycline-induced myocardial damage using cyclic variation of integrated backscatter. Nagai H; Omi W; Yuasa T; Sakagami S; Takata S; Kobayashi K J Am Soc Echocardiogr; 2003 Aug; 16(8):808-13. PubMed ID: 12878989 [TBL] [Abstract][Full Text] [Related]
13. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538 [TBL] [Abstract][Full Text] [Related]
14. Assessment of early-onset chronic progressive anthracycline cardiotoxicity in children: different response patterns of right and left ventricles. Kocabaş A; Kardelen F; Ertuğ H; Aldemir-Kocabaş B; Tosun Ö; Yeşilipek A; Hazar V; Akçurin G Pediatr Cardiol; 2014 Jan; 35(1):82-8. PubMed ID: 23821296 [TBL] [Abstract][Full Text] [Related]
15. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction. Milks MW; Velez MR; Mehta N; Ishola A; Van Houten T; Yildiz VO; Reinbolt R; Lustberg M; Smith SA; Orsinelli DA Am J Cardiol; 2018 Apr; 121(7):867-873. PubMed ID: 29454478 [TBL] [Abstract][Full Text] [Related]
17. Detection of latent anthracycline-induced cardiotoxicity using left ventricular end-systolic wall stress-velocity of circumferential fiber-shortening relationship. Mizuno R; Fujimoto S; Saito Y; Okamoto Y Heart Vessels; 2014 May; 29(3):384-9. PubMed ID: 23780325 [TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. Kumar S; Marfatia R; Tannenbaum S; Yang C; Avelar E Tex Heart Inst J; 2012; 39(3):424-7. PubMed ID: 22719160 [TBL] [Abstract][Full Text] [Related]
19. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Cottin Y; Touzery C; Dalloz F; Coudert B; Toubeau M; Riedinger A; Louis P; Wolf JE; Brunotte F Clin Cardiol; 1998 Sep; 21(9):665-70. PubMed ID: 9755384 [TBL] [Abstract][Full Text] [Related]
20. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab. Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]